Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJordi Bruix, Josep M. Llovet, Jean‐Luc Raoul et al.|Journal of Hepatology|2012Cited by 821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of SorafenibAndrew X. Zhu, Li‐Tzong Chen, Ho Yeong Lim et al.|JAMA|2014Cited by 569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyArmando Santoro, Camillo Porta, Lorenza Rimassa et al.|The Lancet Oncology|2012Cited by 550
PD-1 Blockade in Anaplastic Thyroid CarcinomaJaume Capdevila, Matthew H. Taylor, Lori J. Wirth et al.|Journal of Clinical Oncology|2020Cited by 349